Lenalidomide before and after autologous hematopoietic stem cell transplantation in multiple myeloma

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Tuchman, S A ^a   Chao, N J ^a   Gasparetto, C G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; DRUG ACTIVITY; DRUG EFFICACY; EUROPE; HUMAN; LONG TERM CARE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84862270300     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/712613     Document Type: Review

References (38)

1. Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics, 2010, http://www.cancer.gov/aboutnci/ servingpeople/snapshots/myeloma.pdf
2. Richardson P. G., Schlossman R. L., Weller E., Hideshima T., Mitsiades C., Davies F., Leblanc R., Catley L. P., Doss D., Kelly K., McKenney M., Mechlowicz J., Freeman A., Deocampo R., Rich R., Ryoo J. J., Chauhan D., Balinski K., Zeldis J., Anderson K. C., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 2002 100 9 3063 3067 (Pubitemid 35217050)
3. Dimopoulos M., Spencer A., Attal M., Prince H. M., Harousseau J. L., Dmoszynska A., San Miguel J., Hellmann A., Facon T., Fo R., Corso A., Masliak Z., Olesnyckyj M., Yu Z., Patin J., Zeldis J. B., Knight R. D., Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma The New England Journal of Medicine 2007 357 21 2123 2132 (Pubitemid 350146107)
4. Weber D. M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E. A., Siegel D., Borrello I., Rajkumar S. V., Chanan-Khan A. A., Lonial S., Yu Z., Patin J., Olesnyckyj M., Zeldis J. B., Knight R. D., Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America The New England Journal of Medicine 2007 357 21 2133 2142 (Pubitemid 350146108)
5. Cavo M., Zamagni E., Tosi P., Tacchetti P., Cellini C., Cangini D., De Vivo A., Testoni N., Nicci C., Terragna C., Grafone T., Perrone G., Ceccolini M., Tura S., Baccarani M., Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 2005 106 1 35 39 (Pubitemid 40967171)
6. Zonder J. A., Crowley J., Hussein M. A., Bolejack V., Moore D. F., Whittenberger B. F., Abidi M. H., Durie B. G. M., Barlogie B., Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) Blood 2010 116 26 5838 5841
7. Rajkumar S. V., Hayman S. R., Lacy M. Q., Dispenzieri A., Geyer S. M., Kabat B., Zeldenrust S. R., Kumar S., Greipp P. R., Fonseca R., Lust J. A., Russell S. J., Kyle R. A., Witzig T. E., Gertz M. A., Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 2005 106 13 4050 4053 (Pubitemid 41775908)
8. Rajkumar S. V., Rosiol L., Hussein M., Catalano J., Jedrzejczak W., Lucy L., Olesnyckyj M., Yu Z., Knight R., Zeldis J. B., Bladé J., Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma Journal of Clinical Oncology 2008 26 13 2171 2177
9. Rajkumar S. V., Jacobus S., Callander N. S., Fonseca R., Vesole D. H., Williams M. E., Abonour R., Siegel D. S., Katz M., Greipp P. R., Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial The Lancet Oncology 2010 11 1 29 37
10. Niesvizky R., Jayabalan D. S., Christos P. J., Furst J. R., Naib T., Ely S., Jalbrzikowski J., Pearse R. N., Zafar F., Pekle K., LaRow A., Lent R., Mark T., Cho H. J., Shore T., Tepler J., Harpel J., Schuster M. W., Mathew S., Leonard J. P., Mazumdar M., Chen-Kiang S., Coleman M., BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma Blood 2008 111 3 1101 1109 (Pubitemid 351213388)
11. Richardson P. G., Weller E., Lonial S., Jakubowiak A. J., Jagannath S., Raje N. S., Avigan D. E., Xie W., Ghobrial I. M., Schlossman R. L., Mazumder A., Munshi N. C., Vesole D. H., Joyce R., Kaufman J. L., Doss D., Warren D. L., Lunde L. E., Kaster S., DeLaney C., Hideshima T., Mitsiades C. S., Knight R., Esseltine D. L., Anderson K. C., Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 2010 116 5 679 686
12. Kumar S. K., Lacy M. Q., Hayman S. R., Stewart K., Buadi F. K., Allred J., Laumann K., Greipp P. R., Lust J. A., Gertz M. A., Zeldenrust S. R., Bergsagel P. L., Reeder C. B., Witzig T. E., Fonseca R., Russell S. J., Mikhael J. R., Dingli D., Rajkumar S. V., Dispenzieri A., Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial American Journal of Hematology 2011 86 8 640 645
13. Kumar S. K., Flinn I., Noga S. J., Hari P., Rifkin R., Callander N., Bhandari M., Wolf J. L., Gasparetto C., Krishnan A., Grosman D., Glass J., Sahovic E. A., Shi H., Webb I. J., Richardson P. G., Rajkumar S. V., Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study Leukemia 2010 24 7 1350 1356
14. Jakubowiak A. J., Griffith K. A., Reece D. E., Hofmeister C. C., Lonial S., Zimmerman T. M., Campagnaro E. L., Schlossman R. L., Laubach J. P., Raje N. S., Anderson T., Mietzel M. A., Harvey C. K., Wear S. M., Barrickman J. C., Tendler C. L., Esseltine D. L., Kelley S. L., Kaminski M. S., Anderson K. C., Richardson P. G., Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 multiple myeloma research consortium trial Blood 2011 118 3 535 543
15. Jakubowiak A. J., Dytfeld D., Jagannath S., Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM) 118 Proceedings of the ASH Annual Meeting Abstracts December 2011 631
16. Coleman M., Leonard J., Lyons L., Pekle K., Nahum K., Pearse R., Niesvizky R., Michaeli J., BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrm's macroglobulinemia Leukemia and Lymphoma 2002 43 9 1777 1782 (Pubitemid 34874010)
17. Gay F., Rajkumar S. V., Coleman M., Kumar S., Mark T., Dispenzieri A., Pearse R., Gertz M. A., Leonard J., Lacy M. Q., Chen-Kiang S., Roy V., Jayabalan D. S., Lust J. A., Witzig T. E., Fonseca R., Kyle R. A., Greipp P. R., Stewart A. K., Niesvizky R., Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma American Journal of Hematology 2010 85 9 664 669
18. Kumar S., Flinn I. W., Richardson P. G., Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study 116 Proceedings of the ASH Annual Meeting Abstracts December 2010 621
19. Kumar S., Dispenzieri A., Lacy M. Q., Hayman S. R., Buadi F. K., Gastineau D. A., Litzow M. R., Fonseca R., Roy V., Rajkumar S. V., Gertz M. A., Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma Leukemia 2007 21 9 2035 2042 (Pubitemid 47299979)
20. Mark T., Stern J., Furst J. R., Jayabalan D., Zafar F., LaRow A., Pearse R. N., Harpel J., Shore T., Schuster M. W., Leonard J. P., Christos P. J., Coleman M., Niesvizky R., Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma Biology of Blood and Marrow Transplantation 2008 14 7 795 798 (Pubitemid 351773154)
21. Mazumder A., Kaufman J., Niesvizky R., Lonial S., Vesole D., Jagannath S., Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients Leukemia 2008 22 6 1280 1281 (Pubitemid 351833803)
22. Micallef I. N. M., Ho A. D., Klein L. M., Marulkar S., Gandhi P. J., McSweeney P. A., Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide Bone Marrow Transplantation 2011 46 3 350 355
23. Rajkumar S. V., Gahrton G., Bergsagel P. L., Approach to the treatment of multiple myeloma: a clash of philosophies Blood 2011 118 3205 3211
24. Harousseau J. L., Attal M., Avet-Loiseau H., The role of complete response in multiple myeloma Blood 2009 114 15 3139 3146
25. Nooka A., Kaufman J., Lonial S., The importance of complete response in outcomes in myeloma Cancer Journal 2009 15 6 465 472
26. Cavo M., Tacchetti P., Patriarca F., Petrucci M. T., Pantani L., Galli M., Di Raimondo F., Crippa C., Zamagni E., Palumbo A., Offidani M., Corradini P., Narni F., Spadano A., Pescosta N., Deliliers G. L., Ledda A., Cellini C., Caravita T., Tosi P., Baccarani M., Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study The Lancet 2010 376 9758 2075 2085
27. Palumbo, Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients Journal of Clinical Oncology 2010 28 5 800 807
28. Wheatley K., Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients British Journal of Haematology 2001 113 4 1020 1034 (Pubitemid 32640196)
29. Attal M., Harousseau J. L., Leyvraz S., Doyen C., Hulin C., Benboubker L., Agha I. Y., Bourhis J. H., Garderet L., Pegourie B., Dumontet C., Renaud M., Voillat L., Berthou C., Marit G., Monconduit M., Caillot D., Grobois B., Avet-Loiseau H., Moreau P., Facon T., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 2006 108 10 3289 3294
30. Lokhorst H. M., Van Der Holt B., Zweegman S., Vellenga E., Croockewit S., Van Oers M. H., Von Dem Borne P., Wijermans P., Schaafsma R., De Weerdt O., Wittebol S., Delforge M., Berenschot H., Bos G. M., Jie K. S. G., Sinnige H., Van Marwijk-Kooy M., Joosten P., Minnema M. C., Van Ammerlaan R., Sonneveld P., A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 2010 115 6 1113 1120
31. Spencer A., Prince H. M., Roberts A. W., Prosser I. W., Bradstock K. F., Coyle L., Gill D. S., Horvath N., Reynolds J., Kennedy N., Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure Journal of Clinical Oncology 2009 27 11 1788 1793
32. McCarthy P. L., Owzar K., Anderson K. C., Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 116 Proceedings of the ASH Annual Meeting Abstracts December 2010 37
33. McCarthy P. L., Owzar K., Anderson K. C., Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104 Haematologica 2011 96 S23
34. Attal M., Olivier P., Lauers C. V., Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial Haematologica 2011 96 S23
35. Dimopoulos M. A., Orlowski R. Z., Niesvizky R., Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): analysis of MM-009/010 29 Proceedings of the ASCO Meeting Abstracts June 2011 Chicago, Ill, USA 8009
36. Palumbo A. P., Delforge M., Catalano J., Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older 29 Proceedings of the ASCO Meeting Abstracts June 2011 Chicago, Ill, USA 8007
37. Avet-Loiseau H., Leleu X., Roussel M., Moreau P., Guerin-Charbonnel C., Caillot D., Marit G., Benboubker L., Voillat L., Mathiot C., Kolb B., Macro M., Campion L., Wetterwald M., Stoppa A. M., Hulin C., Facon T., Attal M., Minvielle S., Harousseau J. L., Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) Journal of Clinical Oncology 2010 28 30 4630 4634
38. Neben K., Lokhorst H. M., Jauch A., Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p Blood 2012 119 4 940 948